Home

HOWARD H PIEN

CIK 1187152 · Pres., CEO & Chair. of the Brd · last filed 2020-10-05

HOWARD H PIEN is a Pres., CEO & Chair. of the Brd who has filed 102 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing shows the insider was granted $12.6K of IDRA on Oct 5, 2020. Across all open-market trades the lifetime net is −$282.5K, making them a net seller over the disclosed history. 12 SEC filings were submitted jointly with MEDAREX INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

7

Total Filings

102

Lifetime Open-Market Net

-$282.5K

Filer Profile

Reported Address
C/O MEDAREX, INC
707 STATE ROAD
PRINCETON, NJ 08540
Related Filers
MEDAREX INC — 12 joint filings, latest 2009-09-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Aceragen, Inc. (IDRA) Delisted Director 2,674 $7.22 $19.3K $0 11 2020-10-05
Juno Therapeutics, Inc. (JUNO) Delisted Director 0 — — $0 13 2018-03-07
ImmunoGen, Inc. (IMGN) Delisted Director 2,168 $31.23 $67.7K $0 46 2018-01-03
Sage Therapeutics, Inc. (SAGE) Delisted Director — $8.68 — $0 2 2016-06-24
VNDA Director — $5.09 — $0 8 2015-06-22
VIROPHARMA INC (VPHM) Delisted Director 9,000 — — $0 7 2013-02-25
MEDX Pres., CEO & Chair. of the Brd 0 $34.96 $0 -$282.5K 10 2009-08-31

Recent Filings

102 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-10-05 Aceragen, Inc. (IDRA) Delisted Grant (A) +5,583 $12.6K EDGAR
2020-07-02 Aceragen, Inc. (IDRA) Delisted Grant (A) +7,018 $12.6K EDGAR
2020-05-19 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
2020-04-03 Aceragen, Inc. (IDRA) Delisted Grant (A) +9,666 $12.4K EDGAR
2020-01-06 Aceragen, Inc. (IDRA) Delisted Grant (A) +6,790 $12.6K EDGAR
2019-10-02 Aceragen, Inc. (IDRA) Delisted Grant (A) +4,610 $12.3K EDGAR
2019-07-02 Aceragen, Inc. (IDRA) Delisted Grant (A) +4,469 $11.7K EDGAR
2019-06-06 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
2019-04-02 Aceragen, Inc. (IDRA) Delisted Grant (A) +4,392 $11.4K EDGAR
2019-01-03 Aceragen, Inc. (IDRA) Delisted Grant (A) +2,929 $10.3K EDGAR
Showing 1–10 of 102
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.